| | | | | | | |

Promising Early Results from Mesothelioma Vaccine Trial

ByAlex Strauss

28161928_blood test3Researchers studying a new immunotherapy vaccine for mesothelioma have released early findings from an ongoing clinical trial and the results are promising.

CRS-207 is based on a genetically modified version of Listeria monocytogenes, a bacterium normally associated with the food borne illness, Listeriosis. The drug was designed to induce a powerful immune response against cells that produce mesothelin, which includes mesothelioma and several other kinds of cancer.

In a presentation at the 40th European Society for Medical Oncology in September, lead investigator Raffit Hassan, MD, of the National Cancer Institute said CRS-207 appears to be improving the odds of surviving mesothelioma in inoperable patients.

“The data in this trial continue to be impressive in the front-line treatment of mesothelioma,” said Dr. Hassan. “We are encouraged by the high disease control rate in patients treated with this combination and will continue to evaluate and track the durability of the responses, which are ongoing.”

In the current Phase 1b clinical trial, CRS-207 is being given along with chemotherapy in patients with unresectable malignant pleural mesothelioma. Patients received two treatments with CRS-207 two weeks apart, followed by up to six cycles of standard chemotherapy with pemetrexed and cisplatin and two more CRS-207 treatments. Patients who are “clinically stable” continue to receive CRS-207 every eight weeks as a maintenance therapy.

Of the 34 evaluable patients, 32 (94%) experienced some level of control of their mesothelioma. In 20 of those patients, mesothelioma tumors actually shrunk in size and in the other 12, tumor growth was at least stabilized. The responses lasted for a median of 5.3 months.

Biopsies on three of the patients showed that the drug appeared to attract immune system cells, including CD8+ T-cells, dendritic cells and natural killer cells to the site of the mesothelioma. These immune system cells can then work in conjunction with chemotherapy drugs to destroy mesothelioma cells. Equally importantly, there were no serious treatment-related side effects.

Based on what researchers are calling “compelling data”, the team expects to move into a Phase 3 clinical trial after the current trial wraps up in 2016.

Source:

“Aduro Biotech Announces Phase 1b Mesothelioma Trial Featured in Spotlight Poster at ESMO/ECC”, September 26, 2015, Aduro Biotech website

Similar Posts

Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers
| |

Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

ByAlex Strauss

Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma
| |

Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

ByAlex Strauss

A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

Mesothelioma Still Rising Despite Ban in Ireland
|

Mesothelioma Still Rising Despite Ban in Ireland

ByAlex Strauss

A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

Does Radiotherapy Reduce Mesothelioma Pain?
| |

Does Radiotherapy Reduce Mesothelioma Pain?

ByAlex Strauss

A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

Website Aims to Protect Homeowners from Mesothelioma
|

Website Aims to Protect Homeowners from Mesothelioma

ByAlex Strauss

Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

Ape Virus Shrinks Mesothelioma Tumors in Lab
|

Ape Virus Shrinks Mesothelioma Tumors in Lab

ByAlex Strauss

A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…